ARCHIMED has acquired Stragen Pharma, a leader in complex generics, to leverage its expertise and expand in the growing pharmaceutical market in Switzerland.
Information on the Target
ARCHIMED, a private equity healthcare specialist, has successfully acquired Stragen Pharma through its €1 billion MED Platform I fund. Established in 1990 and located near Geneva, Switzerland, Stragen Pharma is a prominent developer, registrant, and distributor of complex generic medications tailored for patients with life-threatening conditions, particularly those requiring intensive care and thorough monitoring.
In the year 2020, Stragen reported sales of approximately €70 million, with an impressive growth rate exceeding double digits annually. The company’s portfolio consists of 40 unique products, which are marketed in over 60 countries, emphasizing a strong presence in Europe.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in Switzerland
The Swiss pharmaceutical market is recognized for its innovation and has one of the highest concentrations of pharmaceutical companies globally. It is home to many major multinational corporations, alongside a vi
Similar Deals
KKA Partners → BLACKROLL
2025
Liberta Partners → forteq Nidau AG
2023
Verium-Investoren → Zünd Präzisionsoptik und der Optivac
ARCHIMED
invested in
Stragen Pharma
in 2023
in a Management Buyout / Buy-In (MBO) deal
Disclosed details
Transaction Size: $1,062M
Revenue: $77M
Enterprise Value: $1,062M
Multiples
EV/Revenue: 13.9x